Core Scientific, Inc.
CORZQ · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.00 | -0.15 | -109.68 |
| FCF Yield | 8.68% | -1,551.83% | -13.85% | -1.22% |
| EV / EBITDA | 11.98 | -0.23 | 22.71 | 270.90 |
| Quality | ||||
| ROIC | 2.44% | -318.11% | 4.44% | -3.63% |
| Gross Margin | 24.57% | 1.31% | 43.87% | 15.57% |
| Cash Conversion Ratio | -0.26 | -0.10 | -1.20 | 1.95 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.65% | 119.77% | 109.14% | 3,921,715.07% |
| Free Cash Flow Growth | 112.14% | 17.62% | -1,134.02% | -1.69% |
| Safety | ||||
| Net Debt / EBITDA | 7.13 | -0.10 | 3.81 | 2.65 |
| Interest Coverage | 0.10 | -21.79 | 2.96 | -1.43 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 9.73 | 0.76 | 0.87 |
| Cash Conversion Cycle | -147.10 | 6.68 | 468.20 | 402.70 |